Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899196 | 0.74 | — | — | |
| SCHEMBL1436980 | 0.68 | TAAR1 (0.36) | TAAR1KMT2AMAPTMEN1RAB9A | |
| SCHEMBL22652562 | 0.67 | CYP1A2 (0.33) | NPC1RAB9A | |
| SCHEMBL20320620 | 0.67 | HCAR2 (0.50) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL16245717 | 0.65 | NPC1 (0.36) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL12391747 | 0.65 | KMT2A (0.44) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL9402238 | 0.65 | MAPT (0.44) | KMT2AMAPTMEN1NPC1RAB9A | |
| SCHEMBL6230488 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL30801394 | 0.64 | NOTUM (0.32) | KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL9402285 | 0.64 | MAPT (0.43) | KMT2AMAPTMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | TAAR1 4063/4885KMT2A 3318/4885APP 325/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | TAAR1 4070/4885KMT2A 3301/4885APP 323/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | TAAR1 4063/4885KMT2A 3318/4885APP 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.